Feasibility of Lung Cancer RNA Acquisition from a Single Transbronchial or Transthoracic Needle Pass (FASTT Trial)

The biology of non-small cell lung (NSCLC) cancer is complex with considerable variation in the clinical behavior and treatment of tumors with specific genetic mutations, rearrangements, high/low PD-L1 expression, and variable histologies. Many tumor markers for testing at diagnosis are required to assure that all patients with actionable targets are treated with the most efficacious drug. Diagnostic specimens from cytological material need to classify histology, standard mutations, and PDL-1 expression, irrespective of how a patient ’s biopsy is obtained.

Source: Lung Cancer - November 20, 2018 Category: Cancer & Oncology Authors: Travis Dotson, Christina Bellinger, Jing Su, Kris Hansen, Graham E. Parks, James O. Cappellari, Lou Craddock, Hollins Clark, Clifford Howard, W. Jeffrey Petty, Bahrat Prakash, Kounosuke Watabe, Michael Chan, Jonathon Hovda, Lance D. Miller, Jimmy Ruiz Source Type: research